Targeted Therapy Market is Fueled by Precision Medicine Oncology Growth and Biomarker-Based Drug Development|Key Players: F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc., AstraZeneca

Targeted Therapy Market reached US$ 79.18 billion in 2024 and is expected to reach US$ 147.16 billion by 2033, growing at a CAGR of 7.2% during the forecast period 2025-2033.

The latest Targeted Therapy Market Report by DataM Intelligence offers a clear analysis of global trends, market size, key players, and growth drivers. Covering emerging technologies, evolving care models, and regulatory insights, it provides strategic intelligence to help stakeholders navigate the dynamic healthcare landscape through 2025-2033

Download exclusive insights with our detailed sample report (Corporate Email ID gets priority access):
https://www.datamintelligence.com/download-sample/targeted-therapy-market?ophp

Targeted therapies are precision medicines that block the growth of cancer by interfering with specific molecules involved in tumor progression. The market is growing significantly due to rising cancer incidence, expansion of companion diagnostics, and continued breakthroughs in monoclonal antibodies, kinase inhibitors, and biomarker-driven drug development.

Targeted Therapy Market Competitors Overview:

F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc., AstraZeneca, Eisai Inc., Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company., Incyte, Eli Lilly and Company, and Exelixis, Inc., among others.

Important Industry Updates of 2024 and 2025:

In May 2025, the U.S. Food and Drug Administration (FDA) provided accelerated approval for EMRELIS (telisotuzumab vedotin-tllv) developed by AbbVie, for the treatment of adult patients with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression (OE) who have received a prior systemic therapy.

✅ In March 2025, Genmab A/S announced that the Japan Ministry of Health, Labour and Welfare approved TIVDAK (tisotumab vedotin) for the treatment of advanced or recurrent cervical cancer that has progressed on or after cancer chemotherapy. TIVDAK is an antibody drug conjugate that received first approval in Japan for cervical cancer patients.

✅ In October 2024, Genentech a member of the Roche Group, announced that the U.S. FDA approved Itovebi (inavolisib) a targeted therapy, in combination with palbociclib (Ibrance) and fulvestrant, for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer.

Targeted Therapy Market Segments Overview:

∎ By Type (Monoclonal Antibodies, Small Molecules)
∎ By Indication (Leukemia, Breast Cancer, Lung Cancer, GI Cancers, Melanoma, Others)
∎ By Route of Administration (Oral, Parenteral)

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/targeted-therapy-market?ophp

Methodology and Scope:

This Targeted Therapy Market report is developed using a robust research methodology that combines primary interviews, insights from industry experts, and verified secondary sources such as company filings, trade journals, and trusted databases. It follows a bottom-up and top-down approach to ensure data accuracy through triangulation. The scope of the report covers current market trends, growth potential, and strategic developments across global and regional markets.

Regional Overview for Targeted Therapy Market:

⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Looking For Exclusive Full Report? Get it here: https://www.datamintelligence.com/buy-now-page?report=targeted-therapy-market?ophp

The Report Includes:

➡ A descriptive analysis of demand-supply gap, market size estimation, SWOT analysis, PESTEL Analysis and forecast in the global market.
➡ Go-to-market Strategy.
➡ Neutral perspective on the market performance.
➡ Customized regional/country reports as per request and country level analysis.
➡ Potential & niche segments and regions exhibiting promising growth covered.

People Also Ask:

➤ What are the global sales, production, import, and export trends in the Targeted Therapy market?
➤ Who are the top manufacturers, and what are their output, pricing, and revenue figures?
➤ What key opportunities and challenges do vendors face in this market?
➤ Which product types, applications, or end-users are driving growth and holding market share?
➤ What are the main growth drivers and restraints affecting the Targeted Therapy market?

Unlock 360° Market Intelligence with DataM Subscription Services:
https://www.datamintelligence.com/reports-subscription

✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Pipeline Analysis For Drugs Discovery
✅ Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Competitive Landscape

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.